• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

    12/4/25 4:00:00 PM ET
    $AZN
    $CRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $AZN alert in real time by email

    Salesforce (NYSE:CRM), the world's #1 CRM, today announced that AstraZeneca (NASDAQ:AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliver life-changing medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.

    With Agentforce Life Sciences, Salesforce aims to help AstraZeneca unlock a new era of intelligent engagement — redefining customer relationships and accelerating business growth. The partnership will enable teams to focus on strategic customer outcomes and meaningful customer interactions.

    Expanding its remit for AstraZeneca, Salesforce will support Agentforce 360 for Life Sciences as the global, end-to-end engagement solution for AstraZeneca, including:

    • Medical-Commercial Coordination: Consolidating healthcare professional (HCP) insights and surface context across teams.
    • Personalized Engagement: Scaling operations across key account, reimbursement, and field teams with next-best action recommendations. AstraZeneca will also orchestrate and automate digital campaigns across multiple channels based on customer preferences.
    • Model Context Protocol (MCP) Interoperability: Extending its composable architecture with Salesforce's Agent Fabric, AstraZeneca will orchestrate internal and external agent actions across field engagement, commercial operations, and different brands and regions, allowing its care teams and AI agents to work seamlessly together.

    "This partnership with AstraZeneca represents a clear step towards building intelligent, agentic customer engagement in the life sciences industry with their selection of Agentforce Life Sciences for Customer Engagement," said Frank Defesche, SVP and GM of Life Sciences at Salesforce. "Together, we will empower AstraZeneca's teams with the latest technology to deliver personalized engagement and accelerate the delivery of life-changing medicines to patients around the world."

    Learn more:

    • Discover how Salesforce is leading the next era of life sciences transformation
    • Hear from some of the 70+ organizations who selected Agentforce Life Sciences
    • Get a sneak peek of the Agentforce Life Sciences roadmap and transition framework
    • Read about Salesforce's robust partner network, including IQVIA

    About Salesforce

    Salesforce helps organizations of any size become Agentic Enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information.

    Any unreleased services or features referenced here are not currently available and may not be delivered on time or at all. Customers should make their purchase decisions based upon features that are currently available.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251204864712/en/

    Maha Neouchy

    Salesforce

    Public Relations

    408-568-8442

    [email protected]

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $CRM

    CompanyDatePrice TargetRatingAnalyst
    Salesforce Inc.
    $CRM
    12/4/2025$280.00 → $275.00Outperform
    BMO Capital Markets
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    Salesforce Inc.
    $CRM
    10/14/2025$264.00Outperform → Market Perform
    Northland Capital
    Salesforce Inc.
    $CRM
    9/4/2025$335.00 → $280.00Outperform
    BMO Capital Markets
    Salesforce Inc.
    $CRM
    8/26/2025$370.00 → $315.00Outperform
    Oppenheimer
    Salesforce Inc.
    $CRM
    8/15/2025$225.00Underperform → Neutral
    DA Davidson
    Salesforce Inc.
    $CRM
    6/5/2025Buy → Hold
    Erste Group
    More analyst ratings

    $AZN
    $CRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Salesforce Grants Equity Awards to Regrello Employees Under Its Inducement Equity Incentive Plan

    Salesforce (NYSE:CRM), the #1 AI CRM, today announced it has granted equity awards under its 2014 Inducement Equity Incentive Plan (the "Plan") to new employees who joined Salesforce in connection with the acquisition of Regrello. The Plan was adopted by the Salesforce Board of Directors in July 2014, in accordance with New York Stock Exchange Rule 303A.08. Under the Plan, Salesforce granted a total of 222,453 restricted stock units ("RSUs") to 55 employees at Regrello. These RSUs vest over four years, with 25% vesting on the first anniversary of the grant date and the balance vesting quarterly thereafter in 12 equal installments. All equity awards are subject to the employee's continue

    12/23/25 4:00:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

    Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo's ENHERTU with the latest based on DESTINY-Breast05 Phase III trial results AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence. The Food and Drug Administration (FDA) BTD accelerates the development and regulatory review of potential new medicines intended to treat a serious condition and address a significant unmet medical need. T

    12/22/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

    Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca's ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial results Sixteenth Breakthrough Therapy Designation granted by the FDA across the oncology portfolio of Daiichi Sankyo ENHERTU® (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for adult patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and bein

    12/22/25 2:30:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $CRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk David Blair bought $500,722 worth of shares (1,936 units at $258.64), increasing direct ownership by 22% to 10,677 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/18/25 5:10:12 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Morfit G Mason bought $25,015,680 worth of shares (96,000 units at $260.58) (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/8/25 9:30:14 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Kirk David Blair bought $865,827 worth of shares (3,400 units at $254.66), gifted 4,278 shares and received a gift of 4,278 shares, increasing direct ownership by 1,811% to 8,102 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    9/10/25 7:45:16 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $AZN
    $CRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Eng/Cust Success Officer Tallapragada Srinivas converted options into 2,525 shares and covered exercise/tax liability with 1,253 shares, increasing direct ownership by 3% to 47,021 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/23/25 4:36:43 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    EVP & Chief Accounting Officer Reddy Sundeep G. converted options into 574 shares and covered exercise/tax liability with 256 shares, increasing direct ownership by 2% to 13,668 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/23/25 4:34:32 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    President and CLO Niles Sabastian converted options into 1,016 shares and covered exercise/tax liability with 562 shares, increasing direct ownership by 10% to 4,786 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/23/25 4:32:32 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $AZN
    $CRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AZN
    $CRM
    SEC Filings

    View All

    BMO Capital Markets reiterated coverage on Salesforce with a new price target

    BMO Capital Markets reiterated coverage of Salesforce with a rating of Outperform and set a new price target of $275.00 from $280.00 previously

    12/4/25 8:17:32 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    12/22/25 7:47:40 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    12/22/25 7:18:21 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    12/22/25 7:02:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $CRM
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Salesforce Appoints Amy Chang and David B. Kirk to its Board of Directors

    New directors deepen the Board's innovation leadership and technical expertise for the agentic AI era Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced the appointments of Amy Chang, accomplished technology executive, AI entrepreneur, and advisor, and David Kirk, pioneering computer scientist and former NVIDIA chief scientist, to the Salesforce Board of Directors, effective immediately. "I'm thrilled to welcome Amy and David to Salesforce's Board. Their exceptional experience driving innovation and deep technical expertise will be invaluable as we unlock the full potential of human-AI collaboration and digital labor for our customers with Agentforce and across our deeply uni

    7/9/25 9:00:00 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Salesforce Appoints Robin Washington as President and Chief Operating and Financial Officer

    Brian Millham, President and COO, to Retire After 25 Years at Salesforce Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that Robin Washington will become President and Chief Operating and Financial Officer (COFO), effective March 21, 2025. In this newly created role, Washington will lead Salesforce's next phase of transformation—driving profitable growth, operational excellence, and financial strategy—while accelerating the transformation of every company into an Agentforce company, in the new agentic era. A seasoned executive and visionary leader, Washington has spent decades at the forefront of financial and operational strategy at some of the world's most respected com

    2/5/25 4:05:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $AZN
    $CRM
    Financials

    Live finance-specific insights

    View All

    Salesforce Announces Quarterly Dividend

    Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that its board of directors declared a quarterly cash dividend of $0.416 per share. The dividend is payable January 8, 2026 to shareholders of record on December 18, 2025. About Salesforce Salesforce helps organizations of any size become agentic enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20251204068615/en/ Mike Spencer Salesforce Investor Relations [email protected] Carolyn Guss Salesforce Public Relation

    12/4/25 8:49:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Salesforce Delivers Record Third Quarter Fiscal 2026 Results Driven by Agentforce & Data 360

    cRPO up 11% Y/Y; RPO climbs 12% to nearly $60B; Agentforce surpasses 3.2 trillion tokens Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced results for its third quarter fiscal 2026 ended October 31, 2025. Financial Highlights Current remaining performance obligation of $29.4 billion, up 11% year-over-year ("Y/Y") and in constant currency ("CC") Remaining performance obligation of $59.5 billion, up 12% Y/Y Third quarter subscription & support revenue of $9.7 billion, up 10% Y/Y and 9% in CC Third quarter revenue of $10.3 billion, up 9% Y/Y and 8% in CC Third quarter GAAP operating margin of 21.3% and non-GAAP operating margin of 35.5% Third quarter operating cash fl

    12/3/25 4:01:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $CRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Salesforce Inc.

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    11/14/24 1:22:34 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Salesforce Inc.

    SC 13G - Salesforce, Inc. (0001108524) (Subject)

    10/16/24 12:53:21 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Salesforce Inc. (Amendment)

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    2/13/24 5:13:53 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology